# US 2025/0367233 A1 · Novel pharmaceutical composition containing iron and meglumine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367233 A1
- Document ID: US20250367233A1
- Status: Published application
- Kind: A1
- Application number: 19/052,252
- Filed: 2025-02-12
- Published: 2025-12-04
- Earliest claimed: 2024-02-20
- Inventors: Christopher Newton Jobdevairakkam
- Web page: https://patentgrep.com/patent/US20250367233A1

## CPC

- A61K 33/26: Iron; Compounds thereof
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/4858: {Organic compounds}
- A61K 31/133: having hydroxy groups, e.g. sphingosine
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is related to a novel pharmaceutical product containing iron and meglumine. In certain embodiments, the present invention is related to a novel injectable dosage form comprising ferric meglumine as a parenteral iron supplement to treat iron deficiency anemia. In certain embodiments, the present invention is related to a novel oral dosage form comprising ferric meglumine as iron supplement and/or phosphate binder.

## Claims

### Claim 1

A compound comprising iron and meglumine.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound consists of one or more components selected from a group consisting of oxide, hydroxide, water, sodium, chloride, solvent, organic impurities, and elemental impurities.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound is substantially free from organic impurities.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is substantially free from elemental impurities or having elemental impurities at a level below the acceptance level for parenteral products.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the composition is suitable for parenteral administration.

### Claim 7 (depends on 5)

The composition of claim 5, wherein the composition is suitable for oral administration.

### Claim 8 (depends on 5)

A method of treating iron deficient anemia, wherein the method comprises administering the composition of claim 5 to a patient in need thereof.

### Claim 9 (depends on 5)

A method of reducing dietary intake of dietary phosphate, wherein the method comprises administering the composition of claim 5 as an oral phosphate binder.

### Claim 10 (depends on 5)

The pharmaceutical composition of claim 5, wherein the pharmaceutical composition is a solution having a concentration of iron at a level starting from about 1 mg/mL to about 300 mg/mL, and wherein said composition is administered parenterally.

### Claim 11 (depends on 5)

The pharmaceutical composition of claim 5, wherein the pharmaceutical composition is administered orally, and wherein said composition is administered alone or by combining with one or more pharmaceutically acceptable inactive ingredients.

### Claim 12 (depends on 1)

The compound of claim 1, wherein said compound contains iron and meglumine in a molar ratio of iron to meglumine starting from about 1:0.1 to about 1:20 respectively.

### Claim 13 (depends on 1)

A process of making the compound of claim 1, wherein the process involves the step of combining an iron source with meglumine.

### Claim 14 (depends on 13)

A process of claim 13, wherein the iron source is one or more selected from a group consisting of ferric iron, ferrous iron, iron hydroxide, anionic salt of ferric iron, and anionic salt of ferrous iron.

### Claim 15 (depends on 1)

The compound of claim 1, wherein the iron is ferric iron.

### Claim 16 (depends on 1)

The compound of claim 1, wherein the iron is a mixture of ferric and ferrous iron.

### Claim 17 (depends on 1)

The compound of claim 1, wherein the iron is present in the form of iron hydroxide.

### Claim 18 (depends on 17)

The compound of claim 17, wherein the iron hydroxide is a ferric iron compound and/or combination ferric iron and ferrous iron thereof.

### Claim 19 (depends on 13)

The process of claim 13, wherein the iron is anion salt of ferric iron or a mixture of anion salt of ferrous and ferric iron.

### Claim 20 (depends on 19)

The process of claim 19, wherein the anion is one or more selected from the group consisting of chloride, bromide, iodide, acetate, citrate, nitrate, sulfate, and mesylate.

### Claim 21 (depends on 1)

The compound of claim 1, wherein the iron is one or more selected from the group consisting of ferric hydroxide, polymeric ferric hydroxide, ferric oxyhydroxide, polymeric ferric oxyhydroxide, ferric hydroxide gel, hydrated ferric oxide, hydrated ferric hydroxide, hydrated polymeric ferric hydroxide, hydrated polymeric ferric oxyhydroxide, partially neutralized ferric salts and partially neutralized polymeric ferric salts.

### Claim 22 (depends on 1)

The compound of claim 1, wherein the iron meglumine has a weight average molecular weight distribution starting at about 400 daltons to about 7,000,000 daltons.

### Claim 23 (depends on 5)

A method of treating iron deficient anemia, said method comprising administering the composition of claim 5 at a desired dosage level.

### Claim 24 (depends on 23)

The method of claim 23, wherein the method comprises administering iron meglumine composition in combination with other drugs.

### Claim 25 (depends on 5)

A method of reducing phosphate, said method comprising orally administering the iron meglumine composition of claim 5 at a desired dosage level.

### Claim 26 (depends on 1)

A method of treating iron deficient anemia, said method comprising administering a pharmaceutical composition comprising the compound of claim 1.

### Claim 27 (depends on 1)

A method of reducing phosphate, said method comprising orally administering a composition comprising the compound of claim 1.

### Claim 28 (depends on 1)

The compound of claim 1, wherein the compound is a combination of one or more compounds containing iron and meglumine.

### Claim 29 (depends on 1)

The compound of claim 1, wherein the iron meglumine exists as one or more of the type such as, addition compound, hydrogen bonded compound, inclusion complex, occlusion complex, coordinate bonded compound, inorganic complex, covalent bonded compound, metal-organic compound, metal-organic complex, multi-layer compound, core-shell compound.

### Claim 30

A compound comprising iron and meglumine having the following formula:
(Fe)x·(O)y19 (OH)z·(H2O)m·(MGM)n·(L)k
wherein “MGM” represents meglumine having molecular formula C7H17NO5;
“L” represents a ligand selected from a group including carbohydrate, dextran, poly carbohydrate, sugar, dextrose, gluconic acid, derivatives of carbohydrates, substituted carbohydrates, anion, functionalized carbohydrates, starch, acid, base, amine, organic base, organic acid, organic amino compounds;
“Fe” represents predominantly Ferric iron;
“O” represents oxygen;
“OH” represents hydroxy group;
“H2O” represents water molecule;
“x”, “y”, “z” and “n” are integers having a range from about 1 to about 200,000;
“k” and “m” are integers having a range of from about 0 to about 200,000.
